Patent Classification

Treatment, Acid Reflux/Heartburn

1. Reduction of heartburn episodes after ingestion of orange juice
    
2. Reduction of heartburn episodes after ingestion of orange juice

Treatment, Acne

1. Method for treatment of common acne
    
2. Method for the treatment of acne
    
3. Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
    
4. Minocycline oral dosage forms for the treatment of acne
    
5. Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    
6. Topical acne vulgairs medication with a sunscreen
    
7. Method of treating acne
    
8. Treatment of acne using alkonolamine compositions
    
9. Oral composition and method for the treatment of inflammatory cutaneous disorders
    
10. Anti-acne compositions and methods of use
     
11. Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris
     
12. Method of treating acne vulgaris and composition
     
13. Methods of increasing the efficacy of peroxides
     
14. Use of dual compartment mixing container for enzyme mixtures useful to treat acne
     
15. Antibiotic/benzoyl peroxide dispenser
     
16. Use of plant extracts for treatment of acne and furuncle
    
    
17. Method for treating acne

Treatment, Addictive Disorders

1. Method for the treatment of the symptoms of drug and alcohol addiction
    
2. Hapten-carrier conjugates for treating and preventing nicotine addiction
    
3. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
    
4. Treatment of addiction and addiction-related behavior using a composition of topiramate
    
5. Treatment of addiction and addiction-related behavior
    
6. Use of pramipexole for the treatment of addictive disorders

Treatment, Adenocarcinomas

1. Use of substance P antagonists in the treatment of the adenocarcinomas

Treatment, African/Viral,  Hemorrhagic Fever/Ebola

1. Immunogenic compositions and vaccines for Ebola
    
2. Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
    
3. Ebola virion proteins expressed from venezuelan equine encephalitis (VEE) virus replicons
    
4. Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
    
5. Immunization for ebola virus infection
    
6. Method of treating viral hemorrhagic fever
    
7. Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever

Treatment, AIDS/HIV

1. Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
    
2. Process for screening of a binding peptide specific for specific RNA and RNA binding peptides therefrom
    
3. Methods for determining human immunodeficiency virus type 2 (HIV-2) protease sensitivity or resistance to antivirals utilizing an inducible yeast expression system
    
4. Conjugate of an antibody against CCR5 and an antifusogenic peptide
    
5. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
    
6. Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors
    
7. Anti-HIV and anti-tumor peptides and fragments of lysozyme
    
8. Polynucleotides encoding modified HIV-1 gp41 membrane polypeptides
    
9. Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
    
10. Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors
     
11. Method for expression of small antiviral RNA molecules within a cell
     
12. Inhibition of gene expression using RNA interfering agents
     
13. Human immunodeficiency virus (HIV) nucleotide sequences
     
14. Anti-HIV antibody
     
15. Method for measuring resistance of a patient HIV-2 to protease inhibitors
     
16. HIV-1 DNA fragments that hybridize to genomic HIV-1DNA
     
17. Synergistic HIV/AIDS and/or immune disease phyto-nutraceutical composition
     
18. Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human
     
19. Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
     
20. Fusion proteins of non-attenuated HIV regulatory/accessory proteins
     
21. Methods and compositions for impairing multiplication of HIV-1
     
22. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
     
23. Method of screening for drug hypersensitivity reaction
     
24. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
     
25. Non-M, non-O HIV-1 strains, fragments and uses
     
26. Antigens encoded by alternative reading frames from pathogenic viruses
     
27. Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
     
28. HIV-specific CTL inducing peptides and medicaments for preventing or treating AIDS comprising the peptides
     
29. Multimerization of HIV-1 Vif protein as a therapeutic target 
     
30. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
     
31. DNA vaccine compositions and methods of use
     
32. Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV
     
33. Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins
     
34. Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
     
35. Single cell analysis of HIV replication capacity and drug resistance
     
36. Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
     
37. Cellular genes regulated by HIV-1 infection and methods of use thereof
     
38. Core structure of gp41 from the HIV envelope glycoprotein
     
39. Human immunodeficiency virus (HIV) nucleotide sequences
     
40. Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
     
41. Drug for AIDS treatment
     
42. Cyclic peptides and aids vaccines
     
43. Amplification of HIV-1 gag sequences for detection of sequences associated with drug-resistance mutations
     
44. Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human
     
45. Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
     
46. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1(INI1)/hSNF5
     
47. Compositions and methods for eliciting immune or anti-infective responses
     
48. Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41
     
49. Analysis of HIV-1 coreceptor use in the clinical care of HIV-1-infected patients
     
50. GB virus C and methods of treating viral infections
     
51. Cellular genes regulated by HIV-1 infection and methods of use thereof
     
52. Antigenic composition comprising an HIV gag or env polypeptide
     
53. Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
     
54. Variant Tat proteins and methods for use thereof
     
55. Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes
     
56. Method for mutation detection in HIV-1 using pol sequencing
     
57. Methods for treating HIV infected subjects
     
58. Peptide inhibitors of HIV entry
     
59. Expressing gp140 fragment of primary HIV-1 isolate
     
60. Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities
     
61. RANTES mutants and therapeutic applications thereof
     
62. Compositions and methods for treating retroviral infections
     
63. CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
     
64. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
     
65. Pharmaceutical formulations
     
66. Compositions and methods for inhibition of HIV-1 infection
     
67. Sustained release beadlets containing stavudine
     
68. Methods of identifying g-couple receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
     
69. Methods for inhibiting HIV-1 infection
     
70. HIV-specific cytotoxic T-cell responses
     
71. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
     
72. Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
     
73. Combined therapy for treatment of HIV infection
     
74. Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
     
75. Method of treatment of human immunodeficiency diseases
     
76. Detection of HIV
     
77. Rhabdoviruses with reengineered coats
     
78. Method of inducing the production of antibodies to HIV
     
79. Method for determining prognosis of HIV infected individuals
     
80. HIV vaccine
     
81. Methods for inhibiting HIV-1 infection
     
82. Synthetic peptides useful in biological assays for detecting infections caused by group O HIV-1 viruses
     
83. Combination antiviral and interleukin-2 therapy for HIV infection
     
84. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
     
85. Non-M, non-O HIV-1 strains, fragments and uses
     
86. Treatment of lipodystrophy
     
87. Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
     
88. Selective destruction of cells infected with human immunodeficiency virus
     
89. Antiviral composition comprising glycine amide
     
90. Modified HIV-1gag p17 peptide and immunogenic composition
     
91. Human monoclonal antibody against coreceptors for human immunodeficiency virus
     
92. Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
     
93. Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins GP300, P200, and P90/80
     
94. Human immunodeficiency virus immunogenic composition
     
95. Human immunodeficiency virus type 2 (HIV-2) env polypeptide and diagnostic assays
     
96. Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same
     
97. Method for producing recombinant cells for detecting HIV
     
98. Pharmaceutical being used for treating HIV infection, the composition and uses thereof
     
99. Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
     
100. Methods of assessing HIV integrase inhibitor therapy
      
101. Amplification of HIV-1 gag sequences for detection of sequences associated with drug-resistance mutations
      
102. Inhibitors for RNA viruses
      
103. Nucleic acids comprising a post-transcriptional regulatory element (PRE) and their uses
      
104. Stabilized soluble glycoprotein trimers
      
105. HIV related peptides
      
106. Methods of treating HIV infected subjects
      
107. Method and tool for prognosticating HIV infection in a subject by measuring soluble urokinase plasminogen activator receptor, degradation products thereof, and urokinase plasminogen activator receptor
      
108. Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy
      
109. Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
      
110. Methods of monitoring HIV drug resistance
      
111. Method of amplifying or detecting HIV-1 RNA
      
112. Inhibition of retrovirus infection
      
113. Kits for detecting HIV-2
      
114. Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations
      
115. Cloning and expression of HTLV-III DNA
      
116. Process for making antifusogenic fusion peptides that form inclusion bodies
      
117. CD4-independent HIV envelope proteins as vaccines and therapeutics
      
118. Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A
      
119. Inhibitors of HIV membrane fusion
      
120. .beta.-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
      
121. Monoclonal antibodies to human immunodeficiency virus and uses thereof
      
122. HIV envelopolype peptides
      
123. Nef-attachable protein
      
124. Methods for treating HIV-infected patients by the administration of GM-CSF and a protease inhibitor
      
125. Method and kit for detecting resistance to antiviral drugs
      
126. Adenovirus carrying gag gene HIV vaccine
      
127. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
      
128. Inhibition of HIV-1 replication by antisense RNA expression
      
129. Methods for diagnosing and treating autoimmune disease
      
130. Indian green mussel (Perna viridis) as a source of anti-HIV activity
      
131. Use of parasitic biological agents for prevention and control of autoimmune diseases
      
132. Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
      
133. Methods of using cyanovirins to inhibit viral infection
      
134. HIV immunogenic compositions and methods
      
135. Treatment of viral infections
      
136. Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
      
137. Immune enhancing agent for treating HIV infected humans
      
138. Stabilized viral envelope proteins and uses thereof
      
139. HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
      
140. Combination therapy for HIV infections
      
141. HIV vaccine
      
142. Compositions and methods for inhibition of HIV-1 infection
      
143. Combination therapy for HIV infection
      
144. Inhibition of HIV replication using soluble Tat peptide analogs
      
145. Compositions and methods for the treatment of viral disorders
      
146. Soluble lymphotoxin-.beta. receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease
      
147. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) trans-activator of transcription protein for the treatment and prevention of HIV disease
      
148. Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome
      
149. Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
      
150. Method for the development of an HIV vaccine
      
151. Methods for inducing mucosal immune responses
      
152. Selective destruction of cells infected with human immunodeficiency virus
      
153. AIDS prophylactic lubricating composition and devices for its use
      
154. Methods and means for inducing apoptosis by interference in RNA processing
      
155. Efficient ex vivo expansion of cd4+ and cd8- T-cells from HIV infected subjects
      
156. Rantes mutants and therapeutic applications thereof
      
157. Expression of HIV polypeptides and production of virus-like particles
      
158. Delayed progression to aids by a missense allele of the CCR2 gene
      
159. Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins
      
160. Methods of therapy for HIV infection
      
161. Drug combination for the treatment of viral diseases
      
162. Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
      
163. Compounds which inhibit HIV replication
      
164. Biodegradable microbicidal vaginal barrier device
      
165. Treatment of autoimmune diseases
      
166. Compositions and methods for preventing transepithelial transmission of HIV
      
167. Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
      
168. Synthetic HIV-2 envelope genes containing modifications that lead to optimized expression in bacteria
      
169. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
      
170. Vaccines comprising synthetic genes
      
171. Invasive bacterial vectors for expressing alphavirus replicons
      
172. Anti-CCR5 antibodies and kits comprising same
      
173. Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)
      
174. Compositions for treating autoimmune disease
      
175. Antigentically-marked non-infectious retrovirus-like particles
      
176. Method for treatment of immunodeficiency virus infection
      
177. Killer T cell receptor recognizing human immunodeficiency virus
      
178. Methods for producing an immune response against HIV-1
      
179. Use of HIV protease inhibiting compounds
      
180. Method for the development of an HIV vaccine
      
181. Replication defective HIV vaccine
      
182. Channel forming toxins as antiviral agents
      
183. EIA test using nondenatured HIV antigen for early detection of HIV infection
      
184. Polypeptide having human HIV inhibitory activity, a gene encoding the polypeptide, a method to produce the polypeptide
      
185. Method for control and treatment of acquired immunodeficiency syndrome (AIDS)
      
186. Medicinal herbal composition for treating liver diseases and HIV
      
187. Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
      
188. Methods of treating autoimmune diseases with gp39-specific antibodies
      
189. Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
      
190. Methods of using cyanovirins topically to inhibit viral infection
      
191. CD4-independent HIV envelope proteins as vaccines and therapeutics
      
192. Compositions and methods for the treatment and diagnosis of immune disorders
     
     
193. Viral vectors for use in monitoring HIV drug resistance
     
     
194. Method of treating humans with diseases characterized by high secretion of cytokines from macrophage cells
     
     
195. Materials and methods for treating autoimmune disease
     
     
196. Methods and compositions for impairing multiplication of HIV-1
     
     
197. Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
     
     
198. HIV chemokines
     
     
199. Remedy for autoimmune diseases
     
     
200. Method of treating complications in immunodepressed states resulting from HIV infection
     
     
201. Drug combinations containing AZT
     
     
202. Use of cytokines and mitogens to inhibit pathological immune responses
     
     
203.  Inhibitors of HIV infection
     
     
204. Cloned DNA Sequences Related To The Entire Genomic RNA Of Human Immunodeficiency Virus II (HIV-2), Polypeptides Encoded By These DNA Sequences And Use Of These DNA Clones And Polypeptides In Diagnostic Kits
     
     
205. Treatment of auto-immune diseases by photochemotherapy
     
     
206. Method of treating HIV infection with transdermal gel containing mammalian liver extract
     
     
207. Methods of treating autoimmune diseases with a CD86-specific immunotoxin
     
     
208. Method for preventing HIV-1 infection of CD4+ cells
     
     
209. Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof 
     
     
210. Antiviral composition derived from allium CEPA and therapeutic use thereof
      
211. Method of specifying vaccine components for viral quasispecies
      
     
212. Methodologies for the detection of human immunodeficiency virus nucleic acids employing oligonucleotide primer derived from the HIV-1 MVP5180/91 genome
      
213. Compositions for inhibition of membrane fusion-associated events, including human parainfluenza virus transmission
      
     
214. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
      
     
215. HIV envelope polypeptides
      
     
216. Composition and method for prevention of sexually transmitted diseases, including aids
      
     
217. Antibodies directed against binding associated epitopes
      
     
218. Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies
      
     
219. Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
      
     
220. Genetic suppressor elements against human immunodeficiency virus
      
     
221. Melanins with improved ability to inhibit HIV replication
      
     
222. Nucleic acids containing modified human immunodeficiency virus genomes devoid of long terminal repeats encoding non-infectious, replication-deficient, immunogenic retrovirus-like particles
      
     
223. Pathogen-targeted biocatalysts
      
     
224. Methods and compositions for inhibition of viral replication
      
     
225. Azaftig, a proteoglycan for monitoring cachexia and for control of obesity
      
     
226. Chimeric viral proteins
      
     
227. HIV-vaccines
      
     
228. Prophylaxis and therapy of acquired immunodeficiency syndrome
      
     
229. Immunogenic compositions comprising dimeric forms of the human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV) envelope glycoproteins
      
     
230. Peptides that block viral infectivity and methods of use thereof
      
     
231. Use of magnesium based products for the treatment or prophylaxis of autoimmune diseases
      
     
232. Method of using mouse model for evaluation of HIV vaccines
      
     
233. Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV
      
     
234. Method for preventing sexually transmitted diseases
      
     
235. Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
      
     
236. Methods to inhibit replication of infective virus
      
     
237. Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients
      
     
238. Assays for screening for inhibitors of HIV
      
     
239. Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
      
     
240. Method for delaying the onset of AIDS
      
     
241. Process of determining the efficacy of drug treatment in HIV infected subjects
      
     
242. Method for inducing a systemic immune response to an HIV antigen
      
     
243. Methods and compositions for impairing multiplication of HIV-1
      
     
244. Method for treating hemophilia A and B and AIDS and devices used therein
      
     
245. Injection viral treatment
      
     
246. Use of a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections
      
     
247. Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
      
     
248. Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers (Patent: 6,068,858)
      
     
249. Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers (Patent: 6,045,829)
      
     
250. HIV envelope polypeptides
      
     
251. Method for preventing sexually transmitted diseases
      
252. Method for treating AIDS

Treatment, Allergy

1. Methods for deactivating allergens and preventing disease
    
2. Method for treating allergic diseases
    
3. Method for altering allergenic protein in the environment
    
4. Allergy vaccine composition, production method thereof and use of same in allergy treatment
    
5. Biotype diets system: predicting food allergies by blood type
    
6. Immunostimulatory nucleic acids for the treatment of asthma and allergy
    
7. Feline immunoglobulin E molecules and related methods
    
8. Compositions for treating and/or preventing pollinosis
    
9. Allergen vaccine proteins for the treatment and prevention of allergic diseases
    
10. Methods for deactivating allergens and preventing disease
     
11. Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
     
12. Modified fusion molecules for treatment of allergic disease
     
13. Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
     
14. Vaccine for house dust mite allergen using naked DNA
     
15. Methods using eosinophil-specific apoptosis inducer
     
16. Epitope identification and modification for reduced allergenic activity in proteins targeted for transgenic expression
     
17. Protein variants of naturally occurring allergens
     
18. Method for treating allergic rhinitis without adverse effects
     
19. Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-.gamma. secretion and/or treating allergy
     
20. Recombinant allergen with reduced enzymatic activity
     
21. Antibody fragments to JTT-1 protein and cells secreting such antibody fragments
     
22. Chimeric IgE polypeptides and host cells
     
23. JTT-1 protein and methods of inhibiting lymphocyte activation
     
24. Anti-allergy composition comprising wood vinegar- or bamboo vinegar-distilled solution
     
25. Antibodies to JTT-1 protein and cells secreting such antibodies
     
26. Feline immunoglobulin E proteins and compositions thereof
     
27. Concentrated X-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions
     
28. Allergy inhibition
     
29. Delivery of antihistamines through an inhalation route
     
30. Animal model for allergic disorders
     
31. Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
     
32. Live vaccines for allergy treatment
     
33. Mast cell surface antigen, DNA thereof, and antibody against the antigen
     
34. Local nasal immunotherapy with allergen strip for allergic rhinitis
     
35. Pollen allergy-related gene 513
     
36. Method for binding basophils and mast cells
     
37. Stabilized antihistamine syrup
     
38. FcεPE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same
     
39. Proteins producing an altered immunogenic response and methods of making and using the same
     
40. Saliva test for detection of food allergy and intolerance
     
41. Polyclonal antibody composition for treating allergy
     
42. Methods for diagnosis of allergic bronchopulmonary aspergillosis
     
43. Compositions containing both sedative and non-sedative antihistamines
     
44. Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
     
45. Modulation of allergic response
     
46. Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
     
47. Orodispersible tablets containing fexofenadine
     
48. IgE-dependent histamine-releasing factor-binding peptides
     
49. Method for denaturing allergens
     
50. Method for diagnosing immunologic food sensitivity
     
51. Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same
     
52. Pharmaceutical composition against type I allergy and the preparation thereof
     
53. Assay for evaluation of cellular response to allergens
     
54. Herbal remedies for treating allergies and asthma
     
55. Peptide immunogens for vaccination against and treatment of allergy
     
56. Rantes mutants and therapeutic applications thereof
     
57. Compound and method for the prevention and/or the treatment of allergy
     
58. Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
     
59. Methods of preventing or treating allergies
     
60. Allergy treatment method using a rapid immunotherapy protocol
     
61. Natural product composition for decreasing IgE production and treating secondary allergic responses
     
62. Transdermal preparation contacting a loratidine metabolite with antihistaminic activity
    
    
63. Ophthalmic anti-allergy compositions suitable for use with contact lenses
    
    
64. Method for treating allergies
    
    
65. Methods for treating sensitivity to protein allergen using peptides which include a T cell epitope recognized by a T cell receptor specific for the protein allergen
     
    
66. Prophylaxis of allergic disease
     
    
67. Mineral and vitamin combinations for the treatment of stress and allergies
     
    
68. Pheniramine-containing compositions and method for treating allergic responses
     
    
69. Methods and compositions for treating allergic disorders and other disorders using norastemizole in combination with other active ingredients
     
    
70. Symptomatic relief of allergic reactions

Treatment, Altitude Sickness

1. Method for treating acute mountain sickness

Treatment, Alzheimer's/Neurodegenerative Disease

1. Method for prevention and treatment of Alzheimer's disease
    
2. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders
    
3. Immunological control of .beta.-amyloid levels in vivo
    
4. Humanized antibodies that recognize beta amyloid peptide
    
5. Humanized antibodies that recognize beta amyloid peptide
    
6. Monoclonal antibodies that recognize epitopes of amyloid-beta
    
7. Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
    
8. Transplantation of human neural cells for treatment of neurodegenerative conditions
    
9. Differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
    
10. Modulators of amyloid aggregation
     
11. Methods for diagnosing a neurodegenerative condition
     
12. Composition comprising the extract of crude drug complex having neuroprotective activity for preventing and treating stroke and neurodegenerative diseases
     
13. Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
     
14. Combined regulation of neural cell production
     
15. Methods for diagnosis of Alzheimer's Disease in blood samples
     
16. Biomarkers for neurodegenerative disorders 
     
17. Human brain carboxypeptidase B antibodies
     
18. Methods of inhibiting amyloid toxicity
     
19. Gene regulation therapy involving ferritin
     
20. Alzheimer model for drug screening
     
21. Anti-amyloid immunogenic compositions, methods and uses
     
22. Methods of investigating, diagnosing, and treating amyloidosis
     
23. Amyloid .beta. gene vaccines
     
24. Conformationally abnormal forms of tau proteins and specific antibodies thereto
     
25. Synthetic immunogenic but non amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits
     
26. Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
     
27. Adenovirus serotype 30 (Ad30)
     
28. Tools for the diagnosis and treatment of Alzheimer's disease
     
29. Methods and compounds for inhibiting amyloid deposits
     
30. Prolactin induced increase in neural stem cell numbers
     
31. Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical PKM activity
     
32. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
     
33. Soluble cyclic analogues of .beta. amyloid peptide
     
34. Humanin, a polypeptide suppressing neuronal death
     
35. Diagnostic method for alzheimer's disease based on holo-transcobalamin II
     
36. Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
     
37. Amyloid .beta.1-6 antigen arrays
     
38. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
39. Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
     
40. Humanized antibodies that recognize beta amyloid peptide
     
41. Methods for therapy of neurodegenerative disease of the brain
     
42. Method for treatment of neurodegenerative diseases and effects of aging
     
43. Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
44. Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
     
45. Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
46. Methods of treating Alzheimer's disease and other amyloidoses using Hypericum perforatum and derivatives thereof
     
47. IL6RIL6 chimera for the treatment of neurodegenerative diseases
     
48. Method and kit for following neurodegenerative diseases
     
49. Determining the effect of a substance on sequestration, uptake, and accumulation of amyloid in brain cells
     
50. Treatment of alzheimer's disease
     
51. Controlled release microencapsulated NGF formulation
     
52. Transgenic mice comprising a genomic human tau transgene
     
53. Methods for diagnosing a neurodegenerative condition
     
54. Treatments for neurotoxicity in Alzheimer's Disease
     
55. Targeted retrograde gene delivery to motor neurons
     
56. Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
     
57. Treatments for neurotoxicity in Alzheimer's Disease
     
58. Antibodies to a YYX epitope of a mammalian prion protein
     
59. Prevention and treatment of amyloidogenic disease
     
60. Methods for identifying inhibitors of neuronal degeneration
     
61. Prevention and treatment of amyloidogenic disease
     
62. Prevention and treatment of amyloidogenic disease
     
63. Diagnostic methods for drug screening for Alzheimer's disease
     
64. Emu-based compositions for mental well-being and method of use
     
65. Passive immunization of ASCR for prion disorders
     
66. Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
     
67. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
     
68. Active immunization of AScr for prion disorders
     
69. Serine protease BSSP6
     
70. Passive immunization of Alzheimer's disease
     
71. Active immunization for treatment of alzheimer's disease
     
72. Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
     
73. Method of targeting conjugate molecules to mitochondria
     
74. Purified antigen for Alzheimer's disease and methods of obtaining and using same
     
75. Ocular diagnosis of Alzheimer's Disease
     
76. In vitro ischemia model
     
77. Methods for Alzheimer's Disease treatment and cognitive enhancement
     
78. Detection of alzheimer's amyloid by magnetic resonance imaging
     
79. Methods for therapy of neurodegenerative disease of the brain
     
80. Steroidal sapogenins and their derivatives for treating alzheimer's disease
     
81. Prevention and treatment of amyloidogenic disease
     
82. Model for Alzheimer's disease and other neurodegenerative diseases
     
83. Polynucleotides encoding alzheimer's disease secretase
     
84. Prevention and treatment of amyloidogenic disease
     
85. Transgenic animal and methods
     
86. Passive immunization treatment of Alzheimer's disease
     
87. Alzheimer's disease secretase, APP substrates therefor, and uses therefor
     
88. Method of treatment of neuropsychiatric symptoms in patients with Alzheimer's Disease
     
89. Prevention and treatment of amyloidogenic disease
     
90. Alzheimer's disease secretase, APP substrates therefor, and uses therefor
     
91. Method for selecting a transgenic mouse model of alzheimer's disease
     
92. Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits
     
93. Methods and kits for diagnosing Alzheimer's disease from a blood sample
     
94. Diagnosis of tauopathies
     
95. Assays for inhibitors of neuronal transport of Alzheimer's amyloid precursor protein
     
96. Assay for Alzheimer's disease drug development
     
97. Behavior chemotherapy
     
98. Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
     
99. Memory loss treatment formulation
     
100. Methods for improving brain function using leptin or analogs thereof
      
101. Methods for the prevention or treatment of alzheimer's disease
      
102. Method for screening for drugs useful in inhibition of polymerization of a.beta. and tau peptides
      
103. Methods for determining risk of Alzheimer's disease
      
104. Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
      
105. Use of desoxypeganine in the treatment of Alzheimer's dementia
      
106. Method for increasing the concentration of ascorbic acid in brain tissue of a subject
      
107. Assay for compounds which affect conformationally altered proteins
      
108. Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
      
109. Method for administering insulin-like growth factor to the brain
     
     
110. Method of promoting synthesis of nerve growth factor
     
     
111. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
     
     
112. Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
     
     
113. Composition and methods for inhibiting the formation of brain amyloid deposits
     
     
114. Method for administering fibroblast growth factor to the brain 
     
     
115. Method for administering insulin to the brain
      
     
116. Secretases related to Alzheimer's dementia
      
     
117. Intestinal absorption of nicotine to treat nicotine responsive conditions
      
     
118. Solution containing nicotine